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Huntington’s disease is caused by expression of a mutant form of Huntingtin protein containing an expanded polyglutamine
repeat. One possible treatment for Huntington’s disease may be to reduce expression of mutant Huntingtin in the brain via RNA
interference. Unless the therapeutic molecule is designed to be allele-speciﬁc, both wild-type and mutant protein will be
suppressed by an RNA interference treatment. A key question is whether suppression of wild-type as well as mutant
Huntingtin in targeted brain regions can be tolerated and result in a net beneﬁt to patients with Huntington’s disease.
Whether Huntingtin performs essential functions in the adult brain is unclear. Here, we tested the hypothesis that the adult
primate brain can tolerate moderately reduced levels of wild-type Huntingtin protein for an extended period of time. A serotype
2 adeno-associated viral vector encoding for a short hairpin RNA targeting rhesus huntingtin messenger RNA (active vector) was
bilaterally injected into the striatum of four adult rhesus monkeys. Four additional animals received a comparable vector
encoding a scrambled control short hairpin RNA (control vector). General health and motor behaviour were monitored for 6
months. Upon termination, brain tissues were sampled and assessed blindly for (i) huntingtin messenger RNA knockdown; (ii)
Huntingtin protein expression; and (iii) neuropathological changes. Reduction in wild-type huntingtin messenger RNA levels
averaging  30% was measured in the striatum of active vector recipients 6 months post-injection. A widespread reduction in
Huntingtin protein levels was also observed by immunohistochemistry in these animals, with an average protein reduction of
 45% relative to controls measured by western blot analysis in the putamen of active vector recipients. As with control vector
recipients, no adverse effects were observed behaviourally, and no neurodegeneration was found on histological examination of
active vector recipients. Our results suggest that long-term partial suppression of wild-type Huntingtin may be safe, and thus if
a comparable level of suppression of mutant Huntingtin is beneﬁcial, then partial suppression of both wild-type and mutant
Huntingtin may result in a net beneﬁt in patients with heterozygous Huntington’s disease.
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Abbreviations: AAV = adeno-associated virus; GFP = green ﬂuorescent protein
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Huntington’s disease is a fatal neurodegenerative disease affecting
the cerebral cortex (Tabrizi et al., 2009) and subcortical brain
regions (Gabery et al., 2010), with the most pronounced neuronal
degeneration seen in the striatum (Aylward et al., 2004). It is
caused by expression of a mutant, expanded form of Huntingtin
protein. Consequently, Huntingtin itself is a target for therapeutic
intervention. Huntingtin can be reduced in vivo via RNA interfer-
ence using small interfering RNA (Wang et al., 2005) or equiva-
lent short hairpin RNA (Harper et al., 2005). Also, Huntingtin can
be reduced in vivo by antisense therapeutics (Sass and Aronin,
2011).
Each of these approaches is under development for clinical test-
ing, and each has the potential to intervene at the earliest possible
point in the pathogenic pathway of the disease: the expression of
the mutant Huntingtin protein itself. Most of these therapeutic
molecules do not selectively suppress the expression of the
mutant protein, but also suppress expression of the wild-type pro-
tein. An alternative treatment strategy could consist of suppressing
just the mutant allele in heterozygous patients using, for example,
small interfering RNA targeted to polymorphisms in the
Huntington’s disease gene (van Bilsen et al., 2008; Lombardi
et al., 2009). However, a non-allele-speciﬁc therapy in which
both wild-type and mutant protein are suppressed is greatly pre-
ferred to avoid the challenges associated with regulatory approval
of multiple therapeutic molecules (Sah and Aronin, 2011). Yet,
whether suppression of both mutant and wild-type Huntingtin in
targeted brain regions can be tolerated and result in a net beneﬁt
to patients with Huntington’s disease cannot be predicted from
what is currently known.
Although studies support a role for Huntingtin in early develop-
ment (Duyao et al., 1995), its normal function in the adult brain
remains unclear. Huntington’s disease pathogenesis may result in
part from a loss of wild-type Huntingtin function as well as from a
toxic gain of function of mutant Huntingtin (Zuccato et al., 2010).
Development of tissue-speciﬁc knock-out mice (Dragatsis et al.,
2000) and studies in knock-in mice with reduced Hdh expression
(the mouse homologue of Huntingtin) indicate that reduction or
lack of Huntingtin affects brain function (Auerbach et al., 2001).
However, in these animals, Hdh was absent in the early postnatal
period or was reduced throughout development rather than start-
ing in adulthood. Other studies support a role for Huntingtin in
axonal transport (Colin et al., 2008), which may include adequate
production and delivery of brain-derived neurotrophic factor from
the cortex to the striatum (Zuccato and Cattaneo, 2007).
Additionally, Huntingtin has been shown to be required for mitotic
spindle orientation and neurogenesis (Godin et al., 2010).
Whether therapies that reduce both wild-type and mutant
Huntingtin will be beneﬁcial or harmful to patients depends in
part on whether partial reduction of wild-type Huntingtin can be
tolerated long-term in the fully developed adult brain. Conditional
knock-down of Hdh in mice starting at 4.5weeks of age results in
reduced striatal volume in the animals when assessed at 24weeks
of age (Menalled et al., 2009). Conversely, non-allele speciﬁc
suppression of Huntingtin for up to 9 months in rodents has not
been found to cause pathology, although altered expression of
various genes was observed (Boudreau et al., 2009; Drouet
et al., 2009). Here, we expand these observations to adult
non-human primates, reporting that bilateral delivery of an
adeno-associated virus serotype 2 (AAV2) vector encoding an
anti-Huntingtin short hairpin RNA into the striatum of rhesus mon-
keys resulted in  30% sustained reduction of huntingtin messen-
ger RNA and widespread reduction of striatal wild-type Huntingtin
protein levels, estimated at 45% reduction in the putamen, with-
out detectable ill effects or marked pathology 6 months post
administration.
Materials and methods
Animals and treatment groups
Eight adult female rhesus monkeys (Macaca mulatta) weighing
5–7.5kg were obtained from Covance Inc. and housed individually
in the same room on a 12-h light/12-h dark cycle. The animals
were divided in two groups of four age-matched animals:
19.00   1.35 years old (active vector recipients) and 19.75   0.37
years old (control vector recipients), roughly equivalent to 58 years
old in humans (Tigges et al., 1988; Gore and Terasawa, 1991;
Andersen et al., 1999). All behavioural, molecular and histopathologic-
al data measurements were performed blindly with respect to the
treatment group. All procedures were approved by the University of
Kentucky Institutional Animal Care and Use Committee and were con-
ducted in facilities accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care International. Animal care
was supervised by veterinarians skilled in the care and maintenance
of non-human primates.
Development of short hairpin RNA
vectors
Twelve small interfering RNA sequences targeting both rhesus and
human Huntingtin were designed and screened for their ability to
reduce huntingtin messenger RNA in human (HEK293T, American
Type Culture Collection, catalogue number CRL-11268) and rhesus
(LLC-MK2, catalogue number CCL-7) cell lines. An effective candidate
(HD5: 50–GGAGUAUUGUGGAACUUAU–30) was selected for develop-
ment of a viral vector, and the corresponding short hairpin RNA se-
quence was cloned into a plasmid providing AAV2 inverted terminal
repeats and the human U6 promoter. The middle 11nt of the
sequence were scrambled to create a control vector (CTRL5:
50–GGAGUAGUCGUAAUGUUAU–30). The remainder of the AAV
transgene was ﬁlled with an inert DNA sequence to allow for efﬁcient
viral packaging. Vectors were produced from the pAAV-HD5 and
pAAV-CTRL5 plasmids by Virapur Limited Liability Corporation yield-
ing a titre of 2   10
12 vector genomes/ml and undetectable endotoxin
levels (51EU/ml). Vector identity was conﬁrmed by sequencing the
short hairpin RNA-expressing region.
Stereotaxic surgical procedures
All surgical procedures were conducted under isoﬂurane anaesthesia
(1–3%) and sterile ﬁeld conditions. Using MRI-guided techniques,
Hamilton syringes (100ml, model 1710) ﬁtted to 26G side-port needles
and loaded with either AAV2-CTRL5 or AAV2-HD5 were inserted
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in place for 10min. Then, 30ml of AAV was injected into each target
at 2ml/min, using a stereotaxic nanopump (model 310 Plus,
Stoelting Co.). Upon completion, the needles were left in place for
20min then slowly retracted. The syringes were then ﬁtted to new
26G side-port needles and loaded with 60ml of the same AAV2 solu-
tion for bilateral injection into the putamen, 3–4mm caudal from the
caudate nucleus injection site. Two injections of 30ml each were made
dorsoventrally in the putamen, 3-mm apart along a single needle tract.
Finally, two additional injections of 30ml each were made dorsoven-
trally along a single needle tract into the putamen, 3–4mm caudal
from the ﬁrst putamenal injection site. Injection site coordinates and
volumes are summarized in Table 1. An MRI was taken immediately
postoperatively to verify injection placement. Buprenorphine (0.01mg/
kg) was administered subcutaneously pre- and postoperatively, every
12h for 48h.
General health assessment
Baseline body weights were obtained by averaging the last two weight
measurements taken within 45days of AAV delivery. Postoperatively,
body weights were measured every other week for 6 months. Food
consumption was measured daily for 2weeks preoperatively and
6 months postoperatively by counting the number of primate biscuits
consumed (Harlan 2050 Teklad Global 20% protein diet).
Motor function assessment
Home-cage activity levels were measured pre- and post-AAV delivery
using an Actical accelerometer (MiniMitter) mounted on a collar worn
by the animal, and scored as day time (6am to 6pm) and night time
(6pm to 6am) activity. Upper limb motor function was evaluated pre-
and post-AAV delivery using a task consisting of retrieving miniature
marshmallows from an automated receptacle chamber attached to the
home-cage (Walton et al., 2008). Motor performance was electronic-
ally recorded over 12 trials as the time (to within 10ms) for the animal
to retrieve the food from a platform in the receptacle chamber. As
previously reported (Grondin et al., 2003), the automated food retrie-
val task can detect changes in motor function as a result of changes in
basal ganglia function in rhesus macaques, particularly in the caudate
nucleus and putamen. To assess for motor memory preservation, tes-
ting was performed monthly post-AAV administration, without inter-
vening practice between test sessions (Walton et al., 2008).
Necropsy and brain tissue processing
Six months post-surgery, animals were deeply anaesthetized and
euthanized by transcardial saline perfusion. The brain was removed
and both hemispheres cut into consecutive 2-mm thick slabs spanning
the striatum. Using a biopsy needle (2-mm outside diameter), tissue
punches were taken bilaterally in the caudate and putamen for quan-
tiﬁcation of short hairpin RNA and huntingtin messenger RNA expres-
sion. The adjacent slabs were processed so that 40mm coronal sections
could be cut by frozen sliding microtome, and stored in cryoprotectant
solution at  20 C until processed for histopathological evaluations.
Relative quantiﬁcation of short hairpin
RNA and huntingtin messenger RNA
expression
Total RNA was isolated from AAV2-treated brain tissue punches using
the mirVana
TM mitochondrial RNA isolation kit (Applied Biosystems).
Total RNA was also isolated from four caudate and four putamen
punches from each of four age-matched, non-AAV-treated rhesus
monkeys. These samples were pooled separately and used as a control
in the short hairpin RNA and huntingtin messenger RNA expression
analyses of the AAV2-recipient animals. Complementary DNA was
generated using short hairpin RNA-speciﬁc primers and the
TaqMan MicroRNA reverse transcription kit. Custom TaqMan
small RNA assays detected the processed HD5 and CTRL5 short hair-
pin RNAs (Applied Biosystems). Endogenous U18 small nuclear RNA
was used to normalize the expression of the short hairpin RNAs
(i.e. quantify relative to the U18 small nuclear RNA) across samples.
A custom TaqMan assay spanning the junction between exons
14 and 15 of rhesus Huntingtin was used to measure Huntingtin
expression. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
expression was used to normalize the level of Huntingtin gene expres-
sion across samples.
Histopathological examination
One in every twelve 40-mm thick coronal sections throughout the
entire striatum was processed for haematoxylin and eosin and for
Nissl staining. Adjacent sections were processed by immunohistochem-
istry, using procedures described previously (Ai et al., 2003), for the
following proteins: (i) glial ﬁbrillary acidic protein (GFAP 1:5000,
Chemicon, catalogue number MAB360); (ii) the human leukocyte anti-
gen HLA-DR (1:200, Becton Dickinson Biosciences, catalogue number
347360); (iii) Huntingtin (1:2000, Chemicon, catalogue number
MAB2174); and (iv) dopamine- and cAMP-regulated neuronal
phosphoprotein (DARPP-32 1:1000, Santa Cruz, catalogue number
Sc-11365), a cytosolic neuronal phosphoprotein expressed in
GABAergic, medium-sized spiny neurons in the striatum.
Analysis of all injection sites in the caudate (one needle tract per
hemisphere) and putamen (two needle tracts per hemisphere) in each
animal was performed blindly with respect to AAV vectors by a
board-certiﬁed neuropathologist (n = 3–4 sections per brain per type
Table 1 The 10 injection site coordinates and volumes













Caudate nucleus 25.1   0.5 17.1   0.2 +5.3   0.1 30  5.3   0.1 30
Rostral putamen (ventral) 22.3   0.3 21.5   0.3 +10.9   0.2 30  10.9   0.2 30
Rostral putamen (dorsal) 22.3   0.3 18.5   0.3 +10.9   0.2 30  10.9   0.2 30
Caudal putamen (ventral) 19.1   0.3 21.2   0.4 +13.2   0.3 30  13.2   0.3 30
Caudal putamen (dorsal) 19.1   0.3 17.8   0.4 +13.2   0.3 30  13.2   0.3 30
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the Nissl and haematoxylin/eosin stains was evaluated using a semi-
quantitative scale ranging from 0 to 5 as described in Supplementary
Table 1. The severity of astrocytosis or microglial activation seen on
GFAP or HLA-DR stained sections, respectively, was rated using a
separate semi-quantitative scale (Supplementary Table 1). The
lateral-to-medial width and dorsal-to-ventral height of the abnormal-
ities as seen under the microscope were measured by the neuropath-
ologist to assess the size of disruption in tissue around the injection
tract (visualized with Nissl), the area of abnormal astrocytosis
(visualized with GFAP), the area of abnormal microglial response
(visualized with HLA-DR) and any area of reduced immunoreactivity
of Huntingtin or DARPP-32.
Western blot analysis
Protein was isolated and quantiﬁed from a tissue punch taken from the
right and left putamen from each monkey. Thirty micrograms of pro-
tein were loaded in each lane of a Tris–acetate gel (Criterion XT,
Biorad, catalogue number 345-0129) and electrophoresed at 200V
for 45min. The protein was transferred to membranes using the
Invitrogen iBlot transfer system (catalogue number IB101). For detec-
tion of Huntingtin, membranes were exposed to primary antibody
(1:1000, Millipore, catalogue number MAB2166), washed, then
exposed to secondary antibody (1:50000, Millipore peroxidase-
conjugated goat-anti-Mouse IgG, catalogue number AP124P), with
each antibody incubation performed for 1h at room temperature
with gentle agitation. Protein bands were detected using peroxidase-
conjugated goat anti-mouse IgG (1:5000, Millipore catalogue number
AP124P) and the ECL Prime Western Blotting Detection kit
(Amersham catalogue number PRN2108). Chemiluminescence was
captured by direct exposure of the membranes to a charge-coupled
device camera for 30min. Membranes were also re-probed for alpha
tubulin (Abcam catalogue number ab7291) to conﬁrm comparable
amounts of protein loading across lanes.
The amount of Huntingtin protein per lane was quantiﬁed by densi-
tometry using the ‘Gels’ macro provided by the National Institutes
of Health ImageJ software (version 1.42q) following the method
described in the user manual (Ferreira and Rasband, 2011). Brieﬂy,
the background was digitally subtracted from the image using the
macro provided, and then the lanes were manually designated with
identically sized rectangles adequate to fully enclose the Huntingtin
band in each lane. The 1D lane proﬁle plots were generated by the
software (representing the density of the image summed over hori-
zontal raster lines of each rectangle), then the area under each lane’s
plot at the peak corresponding to the Huntingtin band was computed.
These values were normalized by dividing by the value for the density
of the tubulin band in the same lane obtained by the same method.
Statistical analyses
Tests of the null hypotheses of no differences in short hairpin RNA or
huntingtin messenger RNA expression, changes in body weight, food
consumption, upper limb motor function and home-cage activity levels
over time were performed by repeated measures analysis of variance
(ANOVA). Tests of the null hypotheses of no difference in Huntingtin
protein quantiﬁcation by western blot were performed by two-way
(hemisphere   treatment) ANOVA. Semi-quantitative histopathologic-
al ﬁndings (0–5 scale) were analysed using a non-parametric Mann–
Whitney U test. Quantitative histopathological measures (width and
height) were analysed using a one-tailed, unpaired t-test. A P50.05
was considered signiﬁcant in all analyses.
Results
Short hairpin RNA development
Twelve candidate small interfering RNA sequences targeting
Huntingtin at regions of 100% rhesus and human sequence hom-
ology were screened in vitro in HEK293T (human) and LLC-MK2
(rhesus) cell lines. The candidate selected for production of AAV-
based short hairpin RNA (HD5) suppressed huntingtin messenger
RNA by  50% in vitro in LLC-MK2 cells at a concentration of
10pM and 475% at higher concentrations (Fig. 1A). By western
blot, HD5 small interfering RNA suppressed rhesus Huntingtin pro-
tein expression in LLC-MK2 cells by 76.7% compared with cells
transfected with a scrambled, control small interfering RNA (Fig. 1B).
Veriﬁcation of vector function in vitro
and in vivo
The short hairpin RNA sequence corresponding to HD5 was
cloned into a plasmid providing AAV2 inverted terminal repeats
and the human U6 promoter. The middle 11nt of the sequence
were scrambled to create control vector AAV2-CTRL5. Neither
AAV2-CTRL5 nor an AAV2 vector encoding for green ﬂuorescent
protein (AAV2-GFP) suppressed Huntingtin messenger RNA when
transduced into HEK293T cells, while AAV2-HD5 virus suppressed
Huntingtin in these cells by  80% (Fig. 1C).
Using the surgical methods described above, we conducted a
28-day pilot study in one rhesus monkey in which AAV2-HD5 was
co-infused into the striatum at a 1:1 ratio with AAV2-GFP for a
total of 1.5   10
11 vector genomes of each vector infused per
hemisphere. Extensive GFP transgene expression was observed
by ﬂuorescence microscopy in serial brain tissue sections spanning
the caudate and putamen (Supplementary Fig. 1) over an anter-
ior–posterior posterior distance of 12mm. The proportion of this
monkey’s putamen that was positive for GFP was quantiﬁed by
volumetric reconstruction from every 12th 40-mm tissue section
using BioQuant software and found to be  64% of the putame-
nal volume. Huntingtin messenger RNA expression was reduced
by an average of 60.6% in tissue samples captured by laser micro-
dissection from GFP-positive regions, compared with adjacent
GFP-negative regions (Fig. 1D).
Surgical targeting accuracy
A representative example of needle placement in each site is
shown in Fig. 2. Needle placements were conﬁrmed by same-day
post-surgical MRI to be within a radius of 2mm from the planned
targets in all animals. Bilateral AAV delivery into multiple striatal
sites was well tolerated in all eight animals, as supported by the
absence of observable adverse effects such as anorexia, infection,
seizures or vomiting postoperatively.
Short hairpin RNA expression
RNA was isolated from a tissue punch from the caudate and two
punches from the putamen of each hemisphere of each monkey.
Quantitative reverse transcription–polymerase chain reaction
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plementary DNA form of the processed hairpin transcript of
CTRL5 or HD5, respectively. HD5 short hairpin RNA was detected
above background only in monkeys receiving the AAV2-HD5
vector (P50.0001), and CTRL5 short hairpin RNA was detected
above background only in monkeys receiving the AAV2-CTRL5
vector (P50.0001, Fig. 3A).
Huntingtin suppression
The level of huntingtin messenger RNA quantiﬁed from tissue
punches (caudate n=2 and putamen n=4 punches per animal)
was signiﬁcantly reduced in monkeys receiving AAV2-HD5 com-
pared with those receiving AAV2-CTRL5 (P50.05), with no
signiﬁcant differences related to hemisphere or punch location.
Thus, data for the caudate nucleus were combined for the left
and right hemispheres and data for the putamen were combined
across hemispheres and location (rostral and caudal) providing a
single value per brain region per animal. Compared with the mon-
keys receiving CTRL5, the expression of huntingtin messenger
RNA was suppressed by an average of 28% [95% conﬁdence
interval (CI) = 15–41%] in the caudate and 29% (95%
CI = 17–41%) in the putamen of monkeys receiving AAV2-HD5
(Fig. 3B).
Immunostained tissue sections containing the caudate and
putamen showed that Huntingtin protein was substantially
reduced in monkeys receiving AAV2-HD5, including in regions
not limited to the immediate site of the AAV infusion (Fig. 4A
and B). Areas of decreased immunoreactivity seen at each of six
injection sites averaged 5.88   0.53mm (medial–lateral axis) by
6.25   1.01mm (dorsal–ventral axis) in AAV2-HD5 recipients
(P50.05 versus AAV2-CTRL5, Table 2). In contrast, immuno-
staining for DARPP-32, a marker for medium spiny neurons in
the striatum, revealed no signiﬁcant effect of AAV2-HD5
Figure 1 (A) Level of rhesus huntingtin messenger RNA expression (normalized to GAPDH) in LLC-MK2 cells transfected with various
concentrations of candidate anti-huntingtin small interfering RNA (siRNA), relative to levels in mock transfected cells. (B) Western blot of
rhesus Huntingtin (HTT) and beta-actin proteins in lysates from LLC-MK2 cells transfected with anti-huntingtin small interfering RNA
candidate HD1 or HD5. Lanes: (1) untreated cells, (2) cells transfected with HD1, (3) cells transfected with HD5, (4) cells transfected with
a scrambled control small interfering RNA. (C) Level of huntingtin messenger RNA expression in HEK293T cells transduced with
AAV2-CTRL5, AAV2-GFP or AAV2-HD5, relative to levels in mock transduced cells. Data from two separate cell experiments are shown.
(D) Level of rhesus huntingtin messenger RNA expression in striatal brain tissue from two samples of GFP-positive versus two samples of
GFP-negative cells obtained by laser capture microdissection from the pilot monkey co-infused with AAV2-HD5 and AAV2-GFP. Data
from two replicate assays are shown.
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Based on the qualitative reduction in Huntingtin protein seen in
immunostained sections from the slabs of caudate nucleus, rostral
putamen and caudal putamen, and the quantitative reduction in
huntingtin messenger RNA measured by reverse transcription–
polymerase chain reaction assays of punches from adjacent
2-mm thick slabs, the Huntingtin suppression in the striatum
extended at least 10mm along the rostro-caudal axis. The ana-
tomical extent of the Huntingtin suppression obtained in an
AAV2-HD5 recipient is illustrated in Fig. 5, showing the
rostral–caudal series of brain tissue sections containing the infusion
sites, and intervening tissue slabs that were sources of tissue for
molecular measurements.
To further characterize and conﬁrm the protein suppression
observed by immunohistochemistry, protein lysates from tissue
punches from the left and right putamen of each monkey
(at the locations shown in Fig. 5D) were obtained and analysed
by western blot. A single band of the expected molecular weight
for Huntingtin protein ( 350kDa) was detected in each sample
(Fig. 6). Analysis of variance of the normalized densitometric
Figure 3 (A) Expression levels of HD5 short hairpin RNA (shRNA: black bars) and CTRL5 short hairpin RNA (white bars) in tissue punches
from the caudate (two per monkey, one per hemisphere, total n = 8 per group) and putamen (four per monkey, two per hemisphere, total
n = 16 per group) of AAV2-HD5 or AAV2-CTRL5 recipients, relative to the minimum detectable amount by reverse transcription–poly-
merase chain reaction assay. Samples below the detection limit were assigned a value of zero as a raw score, and one as a log-transformed
score. (B) Expression of huntingtin (Htt) messenger RNA levels in the same tissue punches and treatment groups (black bars = AAV2-HD5
recipients, white bars = AAV2-CTRL5 recipients) as a percentage of the average amount detected in monkeys receiving AAV2-CTRL5.
**P50.015.
Figure 2 Representative T1-weighted MRI showing bilateral needle placement in (A) the caudate nucleus, (B) rostral putamen and
(C) caudal putamen. White arrows indicate needle trajectories. Black arrows point out needle tracks in brain tissue.
1202 | Brain 2012: 135; 1197–1209 R. Grondin et al.values revealed no signiﬁcant differences between left and right
hemispheres (P = 0.119) nor interaction between AAV2-HD5 or
CTRL5 treatment and hemisphere (P = 0.195), as expected,
while the effect of AAV2-HD5 versus CTRL5 treatment was
signiﬁcant (P = 0.0027). Compared with the monkeys receiving
CTRL5, the expression of Huntingtin protein in punches
from the putamen of monkeys receiving AAV2-HD2 was
suppressed by an average of 45.8% (observed range: 31.6–
67.5%).
Body weight and food consumption
When each animal’s weight at any post-surgical time point was
compared with its own baseline weight, there was no difference
between AAV groups (P = 0.286), nor any difference between
groups as a function of time (vector by time interaction,
P = 0.159) (Fig. 7A). Food consumption was comparable between
AAV2-HD5 and AAV2-CTRL5 recipients preoperatively and gen-
erally remained within or above baseline level postoperatively for
both treatment groups (Fig. 7B). Transient reduction in appetite
was seen in one CTRL-5 (#93B652) and one HD-5 (#RQ476)
animal mid-study. Animal #93B652 received veterinary care for a
laceration to the mouth (left commissure) and #RQ476 was trea-
ted for gastrointestinal motility problems. Both animals resumed
their normal eating habits within  2 weeks. The other six animals
did not require any veterinary care during the study.
Motor function
Upper limb motor performance times were not adversely affected
by either AAV2-CTRL5 or AAV2-HD5 delivery (Fig. 8A). In fact,
motor performance improved over time for both treatment
groups. Repeated-measures ANOVA yielded a signiﬁcant main
effect of time (P50.05), but no signiﬁcant effect of vector
(P = 0.77) nor interaction between vector and time (P = 0.43).
Motor memory preservation was not adversely affected by
either AAV2-CTRL5 or HD5 delivery as all animals recalled and
performed the retrieval task without intervening practice between
the monthly test sessions.
Home-cage activity levels were quantiﬁed using accelerometers.
The repeated-measures ANOVA for the average daytime activity
level by month revealed no statistically signiﬁcant overall
Figure 4 Immunohistochemistry for Huntingtin protein and DARPP-32. (A and B) Coronal tissue sections immunostained for huntingtin
(Htt) (Chemicon, MAB2174) in the rostral putamen from rhesus monkeys receiving AAV2-CTRL5 (left, #RQ317) or AAV2-HD5 (right,
#RQ476). Arrows highlight region of putamen in the AAV2-HD5 recipient in which staining for Huntingtin protein is reduced. Asterisks
indicate approximate site of needle tip delivering the AAV2-HD5 or AAV2-CTRL5 vectors. (C and D) Coronal tissue sections immunos-
tained for DARPP-32 in the rostral putamen from the same rhesus monkeys as in A and B, respectively. Acb = nucleus accumbens;
Cd = caudate; Cl = claustrum; Cx = cortex; ic = internal capsule; LV = lateral ventricle; Put = putamen. Scale bars = 1mm ( 0.5).
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AAV2-HD5 versus AAV2-CTRL5 (main effect of vector, P = 0.61,
vector by month interaction, P = 0.96, main effect of month,
P = 0.33, Fig. 8B). Similarly, the repeated-measures ANOVA for
the average night time activity level by month revealed no statis-
tically signiﬁcant differences between treatment groups (main
effect of vector, P = 0.58, vector by month interaction, P = 0.99,
Fig. 8C). There were signiﬁcant overall differences in average night
time activity across months, regardless of the vector received by
the monkey (main effect of month, P = 0.03), in part due to a
transient increase in night time activity in the ﬁrst month
post-surgery (Fig. 8C), perhaps reﬂective of post-surgical restless-
ness that later resolved.
Neuropathology
Using three to four sections per marker for each brain, histopatho-
logical examinations were conducted bilaterally on full coronal
sections cut along the anterior–posterior axis at the level where
each needle insertion was made in the striatum. For Nissl, GFAP
and HLA-DR markers, the severity of pathological changes related
to the injection sites or connected structures was low for AAV2-HD5
recipients and comparable to that seen in AAV2-CTRL5 recipients
(Table 2). As illustrated in Fig. 9 for AAV2-HD5 recipient #RQ476,
there was no discernible neuronal loss, or abnormal astrocytosis,
nor evidence of chronic infection, or discernible haemorrhage
(acute or chronic) noted on microscopic evaluation in any of the
animals.
Discussion
To test the hypothesis that the adult brain can tolerate partially
reduced levels of wild-type Huntingtin protein, we developed an
AAV2 vector encoding for a short hairpin RNA (HD5) targeting
rhesus huntingtin messenger RNA. To our knowledge, this is the
ﬁrst report of a study investigating the effects of suppressing
wild-type Huntingtin for as long as 6 months in the adult primate
brain. Six months following bilateral infusion into the caudate
nucleus and putamen of adult rhesus monkeys, we detected
HD5 short hairpin RNA transcripts in the targeted brain regions
and a corresponding suppression of huntingtin messenger RNA
averaging  30% compared with AAV2-CTRL5 animals. We mea-
sured a corresponding suppression of Huntingtin protein in the
putamen averaging  45% bilaterally compared with the putamen
of AAV2-CTRL5 animals. These results are not inconsistent, as a
1:1 ratio of huntingtin messenger RNA to Huntingtin protein sup-
pression is not necessarily expected. Also, the results are not in-
consistent with our in vitro data from the development of
AAV2-HD5 or the in vivo data from the pilot animal, because a
higher level of messenger RNA and protein suppression may be
expected to be measured in a homogenous cell culture or tissue
isolated for transgene expression by laser microdissection.
Although data on huntingtin messenger RNA and protein
reduction were only obtained at termination, our pilot data
(Kaemmerer et al., 2006) as well as other studies utilizing AAV2
vectors in rodents and rhesus monkeys (McCarty et al., 2003;
Sanftner et al., 2005) indicate that expression of the AAV-
delivered short hairpin RNA occurs within a few weeks post-
surgery. Therefore, striatal expression of wild-type huntingtin
messenger RNA and corresponding protein in the AAV2-HD5
recipients was reduced for at least 5 months without causing
motor dysfunction or marked pathology, supporting the interpret-
ation that the adult primate brain can tolerate sustained partial
suppression of wild-type Huntingtin. Other studies using short
hairpin RNA to suppress Huntingtin expression in the mouse stri-
atum using AAV1 vectors have observed toxicity after 15weeks as
revealed by a reduction in immunostaining for DARPP-32
(McBride et al., 2008). These authors found that this toxicity
can be avoided by utilizing mitochondrial RNA-like sequences to
encode the active molecule, rather than short hairpin RNA
sequences such as those used in our study. Nevertheless, we did
not observe toxicity or a signiﬁcant reduction in DARPP-32
immunostaining resulting from expression of either AAV2-HD5
or AAV2-CTRL5 short hairpin RNA in our study.
Prior studies investigating Huntingtin reduction in the brain have
utilized normal (Drouet et al., 2009) or transgenic rodents (Harper
et al., 2005; Wang et al., 2005) or have investigated Huntingtin
reduction starting in early development (Dragatsis et al., 2000).
There are legitimate concerns that reduction of wild-type
Huntingtin expression in the brain of patients with Huntington’s
disease, concomitant with reduction in the disease-causing mutant
protein, may have negative as well as beneﬁcial effects
(Sah and Aronin, 2011). However, the results of our study in
adult rhesus monkeys suggest that the negative effects might be
minimal relative to the beneﬁt that could result from reduction of
Table 2 Histopathological ﬁndings
Markers AAV2-CTRL5 AAV2-HD5 P-value
Mean   SEM Mean   SEM
Scale (0–5)
Nissl/haematoxylin/eosin 0.34   0.12 0.88   0.44 NS
GFAP 0.63   0.23 1.23   0.12 NS
HLA-DR 0.33   0.10 0.56   0.12 NS
Width (mm)
Nissl/haematoxylin/eosin 0.90   0.50 1.52   0.53 ns
GFAP 2.96   1.06 4.92   0.54 ns
HLA-DR 1.23   0.55 2.04   0.99 ns
DARPP32 1.67   0.97 1.77   0.76 ns
Huntingtin 1.69   0.73 5.88   0.53 50.002
Height (mm)
Nissl/haematoxylin/eosin 0.92   0.46 1.52   0.44 ns
GFAP 3.17   1.23 5.75   0.51 ns
HLA-DR 1.06   0.47 2.42   1.14 ns
DARPP32 2.48   1.46 2.15   1.00 ns
Huntingtin 2.69   1.46 6.25   1.01 50.046
Scale = blind semi-quantitative ratings on a 0–5 ordinal severity scale, where
0 = no or minimal pathology, and 5 = severe pathology (Supplementary Table 1).
‘Width’ and ‘Height’ = measurements at the injection site related to cell loss
(Nissl), astrocytosis (GFAP) or microglial response (HLA-DR). For DARPP-32 and
huntingtin, ‘Width’ and ‘Height’, denote the area in terms of decreased immu-
noreactivity. For each marker, data are expressed as the averaged results for all six
needle insertion sites per animal providing a single, overall value of the pathology
in the brain for all sites combined. NS = not signiﬁcant (P40.05), one-tailed,
Mann–Whitney U-test; ns = not signiﬁcant (P40.05), one-tailed, unpaired t-test.
1204 | Brain 2012: 135; 1197–1209 R. Grondin et al.Figure 5 Immunohistochemistry for Huntingtin (Htt) protein
and tissue punch location for polymerase chain reaction (PCR)
and western blot (WB) analyses. (A, C and E) Full coronal tissue
sections immunostained for Huntingtin in the caudate nucleus
(A), rostral putamen (C) and caudal putamen (E) are shown from
a rhesus monkey receiving AAV2-HD5. Arrows highlight regions
in which staining for Huntingtin protein is bilaterally reduced for
Figure 5 Continued
each brain target over a distance of at least 10mm along the
rostro-caudal axis. (B and D) Diagrams of coronal tissue sections
adjacent to those immunostained for Huntingtin depicting the
location of tissue punches in the caudate nucleus and putamen
used to assess huntingtin messenger RNA levels by polymerase
chain reaction (ﬁlled circles, B and D) and Huntingtin protein
expression by western blots (open circles, D). Acb = nucleus
accumbens; Cd = caudate nucleus; ic = internal capsule;
GPe = external globus pallidus; GPi = internal; globus pallidus;
Put = putamen; Rt = Right. Scale bars = 5mm.
Figure 6 (A) Western blot of Huntingtin protein in tissue
punches from left (L) and right (R) putamen of the four monkeys
receiving AAV-CTRL5 (top) or the four receiving AAV-HD5
(bottom) Lanes 2–5 and 7–10 (Lanes 1, 6 and 11 are protein
standards). Insets show same blot re-probed and imaged (at a
shorter exposure time) for tubulin protein. Numbers in each lane
provide the ratio of Huntingtin to tubulin densitometry values.
(B) Amount of Huntingtin protein (normalized to tubulin) in left
or right putamen of each group of monkeys, relative to average
amount in left putamen of monkeys receiving AAV-CTRL5,
**P50.01 AAV-HD5 versus AAV-CTRL5 by hemisphere.
NS = left versus right putamen difference in AAV-CTRL5
recipients is not statistically signiﬁcant.
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ranging from 40% to 50% is beneﬁcial in patients.
There are a number of limitations to the interpretation of our
results. First, the length of our study was 6 months, roughly
equivalent to 18 months in humans considering that rhesus mon-
keys age at a rate approximately three times faster (Tigges et al.,
1988; Gore and Terasawa, 1991; Andersen et al., 1999). In con-
trast, the time required for mutant Huntingtin to result in overt
pathology in humans is at least a few decades. It is possible that
the time required for a reduction in wild-type Huntingtin to have
ill effects may also be measured in years. Also, our sample size
may not have allowed detection of mildly negative effects. Since
Huntingtin is not a secreted protein, the reduction in Huntingtin
protein levels was limited to those cells transduced by the AAV2
vector, (predominantly neurons; Tenenbaum et al., 2004), which
would be 5100% of the neurons in any given region. Conversely,
since we measured huntingtin messenger RNA reduction in tissue
punches, not in individual cells (as even with laser microdissection,
there is no standard against which to determine absolute
Huntingtin reduction in a single cell), it is possible that we
achieved substantially 430% reduction of huntingtin messenger
Figure 8 (A) Change in motor performance on the hand/
arm-retrieval task over time. All animals recalled and were
able to perform the task after AAV2 delivery. Overall, upper
limb motor function was not adversely affected by AAV2-
CTRL5 (open bars) or AAV2-HD5 delivery (ﬁlled bars). (B and C)
No signiﬁcant differences were seen in day time (B) or night
time (C) home-cage activity levels between AAV2-CTRL5
(open circles) and AAV2-HD5 recipients (ﬁlled circles).
Bsl = baseline.
Figure 7 Change in body weight (A) and food consumption
(B) over time. The effect of AAV2-HD5 (anti-huntingtin short
hairpin RNA) administration on body weights and food con-
sumption was comparable to that recorded in control animals
(AAV2-CTRL5). The arrows indicate AAV delivery.
Bsl = baseline.
1206 | Brain 2012: 135; 1197–1209 R. Grondin et al.Figure 9 Brain tissue pathology. Representative coronal tissue sections stained for haematoxylin and eosin (H&E; A and B), Nissl
(C and D), glial ﬁbrillary acidic protein (GFAP; E and F) and HLA-DR (G and H) in the region of the rostral putamen from a rhesus monkey
receiving AAV2-HD5 (#RQ476). Histopathological changes in AAV2-HD5 recipients were comparable to those seen in the AAV2-CTRL5
recipients (Table 2). There was no discernible neuronal loss or abnormal astrocytosis noted on microscopic evaluations. Arrows indicate
approximate site of needle tip delivering the AAV2-HD5 vectors. Scale bars: A, C, E and G = 400mm(  2). Scale bars for the higher
magniﬁcation inset panels from the left column = 20mm(  40, B and D) and 50mm(  20, F and H).
WT huntingtin suppression in striatum Brain 2012: 135; 1197–1209 | 1207RNA in individual neurons (e.g. up to 100% reduction in 30% of
the neurons). Nevertheless, neuronal loss was not observed.
However, it is possible that reduction of wild-type Huntingtin
protein in astrocytes, as well as neurons, could have different ef-
fects than observed in our study. Finally, it is possible that sup-
pression of wild-type Huntingtin has negative effects on other
factors that we did not measure, such as the rate of neurogenesis
(Godin et al., 2010). Despite these limitations, the results of our
study in adult rhesus monkeys extend those obtained in rodents
(Boudreau et al., 2009; Drouet et al., 2009) and suggest that
non-allele-speciﬁc, partial reduction of Huntingtin expression in
striatal brain regions may be a viable approach for the treatment
of Huntington’s disease. Because use of anti-Huntingtin RNA
interference offers the possibility of a disease-modifying treatment,
it may be one of the more promising therapies under development
for this devastating disease for the foreseeable future.
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